Increased cytotoxic potential of microglia from ALS-transgenic mice

GLIA

Volumn 48, Issue 2, 2004, Pages 179-182

  Weydt, Patrick ^a   Yuen, Eric C ^a   Ransom, Bruce R ^a   Möller, Thomas ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Amyotrophic lateral sclerosis; Microglia; Neurodegeneration; Neuroinflammation; SOD1

Indexed keywords

INTERLEUKIN 6; LIPOPOLYSACCHARIDE; SUPEROXIDE DISMUTASE; TUMOR NECROSIS FACTOR ALPHA;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOTOXICITY; FEMALE; GENE; GENE EXPRESSION; GENE MUTATION; MALE; MICROGLIA; MOTOR NEURON DISEASE; MOUSE; NERVE DEGENERATION; NONHUMAN; PRIORITY JOURNAL; SOD1 GENE; TRANSGENIC MOUSE;

AGE FACTORS; AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; ANIMALS, NEWBORN; CELL DEATH; CELLS, CULTURED; DISEASE MODELS, ANIMAL; GLIOSIS; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; MALE; MICE; MICE, TRANSGENIC; MICROGLIA; MUTATION; SUPEROXIDE DISMUTASE; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 9144230806     PISSN: 08941491     EISSN: None     Source Type: Journal    
DOI: 10.1002/glia.20062     Document Type: Article

References (22)

1. Akassoglou K, Probert L, Kontogeorgos G, Kollias G. 1997. Astrocyte-specific but not neuron-specific transmembrane TNF triggers inflammation and degeneration in the central nervous system of transgenic mice. J Immunol 158:438-445.
2. Alexianu ME, Kozovska M, Appel SH. 2001. Immune reactivity in a mouse model of familial ALS correlates with disease progression. Neurology 57:1282-1289.
3. Benveniste EN, Sparacio SM, Norris JG, Grenett HE, Fuller GM. 1990. Induction and regulation of interleukin-6 gene expression in rat astrocytes. J Neuroimmunol 30:201-212.
4. Campbell IL, Abraham CR, Masliah E, Kemper P, Inglis JD, Oldstone MBA, Mucke L. 1993. Neurologic disease induced in transgenic mice by cerebral overexpression of interleukin-6. Proc Natl Acad Sci US 90:10061-10065.
5. Clement AM, Nguyen MD, Roberts EA, Garcia ML, Boillee S, Rule M, McMahon AP, Doucette W, Siwek D, Ferrante RJ, Brown RH Jr, Julien JP, Goldstein LS, Cleveland DW. 2003. Wild-type nonneuronal cells extend survival of SOD1 mutant motor neurons in ALS mice. Science 302:113-117.
6. Giulian D, Baker TJ. 1986. Characterization of ameboid microglia isolated from developing mammalian brain. J Neurosci 6:2163-2178.
7. Gong YH, Parsadanian AS, Andreeva A, Snider WD, Elliott JL. 2000. Restricted expression of G86R Cu/Zn superoxide dismutase in astrocytes results in astrocytosis but does not cause motoneuron degeneration. J Neurosci 20:660-665.
8. Gruol DL, Nelson TE. 1997. Physiological and pathological roles of interleukin-6 in the central nervous system. Mol Neurobiol 15:307-339.
9. Gurney ME, Pu HF, Chiu AY, Dalcanto MC, Polchow CY, Alexander DD, Caliendo J, Hentati A, Kwon YW, Deng HX, Chen WJ, Zhai P, Sufit RL, Siddique T. 1994. Motor-neuron degeneration in mice that express a human Cu,Zn superoxide-dismutase mutation. Science 264:1772-1775.
10. Hall ED, Oostveen JA, Gurney ME. 1998. Relationship of microglial and astrocytic activation to disease onset and progression in a transgenic model of familial ALS. Glia 23:249-256.
11. He BP, Wen W, Strong MJ. 2002. Activated microglia (BV-2) facilitation of TNF-alpha-mediated motor neuron death in vitro. J Neuroimmunol 128:31-38.
12. Marikovsky M, Ziv V, Nevo N, Harris-Cerruti C, Mahler O. 2003. Cu/Zn superoxide dismutase plays important role in immune response. J Immunol 170:2993-3001.
13. Möller T, Hanisch UK, Ransom BR. 2000. Thrombin-induced activation of cultured rodent microglia. J Neurochem 75:1539-1547.
14. Nguyen MD, D'Aigle T, Gowing G, Julien JP, Rivest S. 2004. Exacerbation of motor neuron disease by chronic stimulation of innate immunity in a mouse model of amyotrophic lateral sclerosis. J Neurosci 24:1340-1349.
15. Ono S, Hu J, Shimizu N, Imai T, Nakagawa H. 2001. Increased interleukin-6 of skin and serum in amyotrophic lateral sclerosis. J Neurol Sci 187:27-34.
16. Poloni M, Facchetti D, Mai R, Micheli A, Agnoletti L, Francolini G, Mora G, Camana C, Mazzini L, Bachetti T. 2000. Circulating levels of tumour necrosis factor-alpha and its soluble receptors are increased in the blood of patients with amyotrophic lateral sclerosis. Neurosci Lett 287:211-214.
17. Pramatarova A, Laganiere J, Roussel J, Brisebois K, Rouleau GA. 2001. Neuron-specific expression of mutant superoxide dismutase 1 in transgenic mice does not lead to motor impairment. J Neurosci 21:3369-3374.
18. Strong MJ. 2003. The basic aspects of therapeutics in amyotrophic lateral sclerosis. Pharmacol Ther 98:379-414.
19. Troost D, Claessen N, van den Oord JJ, Swaab DF, de Jong JM. 1993. Neuronophagia in the motor cortex in amyotrophic lateral sclerosis. Neuropathol Appl Neurobiol 19:390-397.
20. Weydt P, Weiss MD, Möller T, Carter GT. 2002. Neuro-inflammation as a therapeutic target in amyotrophic lateral sclerosis. Curr Opin Invest Drugs 3:1720-1724.
21. Weydt P, Hong SY, Kliot M, Möller T. 2003. Assessing disease onset and progression in the SOD1 mouse model of ALS. NeuroReport 14:1051-1054.
22. Zhu S, Stavrovskaya IG, Drozda M, Kim BY, Ona V, Li M, Sarang S, Liu AS, Hartley DM, Wu du C, Gullans S, Ferrante RJ, Przedborski S, Kristal BS, Friedlander RM. 2002. Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature 417:74-78.